Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of ZYTIGA® (abiraterone acetate) under an accelerated regulatory review procedure. ZYTIGA is a novel, once-daily, oral, androgen biosynthesis inhibitor developed for the treatment of prostate cancer...
More...
More...